PFM Health Sciences’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

PFM Health Sciences’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-145,147	Closed	-$14.8M	–	90
2023 Q2	$14.8M	Buy	+145,147	New	+$13.7M	0.57%	47
2020 Q2	–	Sell	-97,864	Closed	-$14.1M	–	88
2020 Q1	$14.1M	Buy	+97,864	New	+$18.9M	1.16%	34

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PFM Health Sciences's RETA Position: Q3 2023 in Review

PFM Health Sciences sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 145,147 shares — an estimated $14.8M sold.

PFM Health Sciences first reported a position in RETA in Q1 2020 and held it in 2 quarters. The position peaked at $14.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

PFM Health Sciences reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
PFM Health Sciences sold 145,147 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $14.8M.
PFM Health Sciences first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 2 quarters.
PFM Health Sciences's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $14.8M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on PFM Health Sciences's 13F filing for Q3 2023, filed 14 Nov 2023.